AzTrials
AzTrials

Silicon Oil Effect on CorneaNCT06861946

Silicone Effect on Corneal Endothelium and Corneal Biomechanics Using Corvis ST

An observational study of Silicon Oil Effect on Cornea and Corneal Biomechanics, run by Beni-Suef University at 2 sites in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Brief Summary The goal of this observational study is to investigate the effects of silicone oil tamponade on corneal endothelial cell density (ECD), morphology, and biomechanics in patients undergoing vitrectomy for retinal detachment (20 patients, 20 eyes). Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
What is being tested?
Corvis ST and Conrneal endothelial cell density
How many people
80 participants
Where
2 sitesEgypt
Study dates
1 May 2022to 31 Dec 2024
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Patients undergoing vitrectomy with silicone oil tamponade for the treatment of rhegmatogenous retinal detachment (RRD).

Who may be able to join

  • Patients undergoing vitrectomy.
  • Clear cornea.
  • Central corneal thickness (CCT) ≥ 500 µm.
  • Age between 20 and 50 years.

Who cannot join

  • History of intraocular surgery.
  • Ocular pathologies, such as corneal scarring or dystrophy.
  • Advanced keratoconus.

Trial locations and contacts

2 sites in 1 country.

Egypt2 sites
  • Fayoum University Hospital

    Al Fayyum, Faiyum Governorate

  • Misr University For Science and Technology

    Giza

Other trials in Egypt

About this study

Brief Summary

The goal of this observational study is to investigate the effects of silicone oil tamponade on corneal endothelial cell density (ECD), morphology, and biomechanics in patients undergoing vitrectomy for retinal detachment (20 patients, 20 eyes). The main questions it aims to answer are:

Read more

How does silicone oil tamponade affect corneal ECD, morphology, and biomechanics over 6 months postoperatively?

Are these changes associated with variations in best-corrected visual acuity (BCVA) or intraocular pressure (IOP)?

Comparison group: Researchers will compare preoperative measurements to 1-, 3-, and 6-month postoperative assessments to evaluate changes in endothelial parameters and corneal biomechanics.

Participants will:

Undergo preoperative and postoperative assessments (at 1, 3, and 6 months) using specular microscopy (to measure ECD, coefficient of variation, hexagonality) and Corvis ST (to evaluate biomechanical properties: Stress-Strain Index and deformation amplitude).

Have BCVA and IOP measured at each follow-up visit to track clinical outcomes.

Read the detailed description

This prospective observational study evaluates the impact of silicone oil tamponade on corneal endothelial integrity and biomechanical properties in patients undergoing vitrectomy for retinal detachment. Below is an expanded description of the study protocol, emphasizing methodological rigor and technical specifics.

Study Design Type: Single-center, prospective, longitudinal observational study. Primary Objective: To quantify postoperative changes in corneal endothelial cell density (ECD), morphology, and biomechanical stability over a 6-month period following silicone oil tamponade.

Secondary Objectives:

Correlate corneal changes with clinical outcomes (BCVA, IOP).

Identify risk factors for endothelial cell loss or biomechanical weakening.

Rationale for Time Points: Assessments at 1, 3, and 6 months were selected to capture early postoperative stress responses (1 month), intermediate healing (3 months), and longer-term stabilization (6 months), aligning with standard vitrectomy follow-up protocols.

Participant Enrollment Recruitment: Consecutive patients scheduled for vitrectomy with silicone oil tamponade at a tertiary eye care center.

Informed Consent Process: Participants received detailed verbal and written explanations of study procedures, risks, and benefits prior to enrollment.

Data Collection Procedures Clinical and Imaging Assessments

Best-Corrected Visual Acuity (BCVA):

Measured using Snellen charts under standardized lighting conditions.

Converted to logMAR for statistical analysis.

Intraocular Pressure (IOP):

Assessed via Goldmann applanation tonometry (calibrated weekly), with three consecutive readings averaged.

Corneal Endothelial Analysis:

Specular Microscopy (Konan Noncon Robo NSP-9900):

Parameters:

Endothelial Cell Density (ECD): Cells/mm².

Coefficient of Variation (CV): Reflects cell size variability (polymegathism).

Hexagonality: Percentage of hexagonal cells (pleomorphism).

Protocol: Central corneal measurements taken in triplicate, with the median value recorded.

Corneal Biomechanical Evaluation:

Corvis ST (Oculus Optikgeräte GmbH):

Parameters:

Stress-Strain Index (SSI): Quantifies corneal stiffness.

Deformation Amplitude (DA): Maximum corneal displacement during air-puff applanation.

Protocol: Three valid scans per eye, performed under mesopic conditions.

Follow-Up Protocol Baseline: Preoperative assessment within 1 week of surgery.

Postoperative: Follow-up visits at 1, 3, and 6 months (±7 days), including:

BCVA and IOP measurement.

Specular microscopy and Corvis ST imaging.

Documentation of complications (e.g., corneal edema, elevated IOP).

Quality Assurance Measures

Equipment Calibration:

Specular microscopy and Corvis ST devices underwent daily calibration checks and quarterly manufacturer servicing.

Standardized Protocols:

All measurements performed by a single trained ophthalmologist to minimize inter-observer variability.

Consistent time-of-day scheduling for IOP assessments (9 AM-11 AM) to control diurnal fluctuations.

Blinded Analysis:

Endothelial and biomechanical data were analyzed by masked investigators unaware of clinical outcomes or time points.

Data Management and Statistical Analysis

Data Storage:

Clinical and imaging data stored in a HIPAA-compliant REDCap database with role-based access.

Regular backups to encrypted cloud storage.

Statistical Methods:

Primary Analysis: Linear mixed-effects models to evaluate longitudinal changes in ECD, SSI, and DA.

Secondary Analysis: Pearson/Spearman correlations between endothelial parameters, biomechanics, and BCVA/IOP.

Missing Data: Multiple imputation used for sporadic missing follow-up data (<10% attrition anticipated).

Software: Analyses performed using R (v4.3.1) and SPSS (v28.0).

Ethical and Safety Considerations

Adverse Event Management:

Complications (e.g., corneal decompensation, IOP spikes) were managed per institutional guidelines and reported to the IRB.

Protocol Compliance:

Internal audits conducted quarterly to ensure adherence to GCP and study protocols.

Technical Rationale Silicone Oil Tamponade: While effective for retinal reattachment, silicone oil may mechanically stress the corneal endothelium or alter aqueous humor dynamics, potentially accelerating cell loss.

Biomechanical Relevance: Corneal stiffness (SSI) and deformability (DA) are critical for refractive stability and surgical planning (e.g., cataract surgery post-vitrectomy).

Clinical Implications

This study aims to provide evidence-based recommendations for:

Timing of silicone oil removal to mitigate corneal damage.

Enhanced monitoring strategies for high-risk patients.

Personalized interventions to preserve endothelial health.

Being tested
Corvis ST, Conrneal endothelial cell density
Keywords
Corneal biomechanics, Specular microscopy, silicon oil, endothelial cell density

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Corvis STDiagnostic test

    Also called Corneal Biomechanics

    Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

    Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

  • Conrneal endothelial cell densityDiagnostic test

    The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

    Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

    Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

Study groups in NCT06861946
Study groupRoleWhat they receive
Group (A)Vitrectomy with 1000 cSt silicone oil.
Receives: Diagnostic Test: Corvis ST; Diagnostic Test: Conrneal endothelial cell density
group (B)Phaco vitrectomy with 1000 cSt silicone oil.
Receives: Diagnostic Test: Corvis ST; Diagnostic Test: Conrneal endothelial cell density
group (C)Vitrectomy with 5000 cSt silicone oil.
Receives: Diagnostic Test: Corvis ST; Diagnostic Test: Conrneal endothelial cell density
group (D)Phaco vitrectomy with 5000 cSt silicone oil.
Receives: Diagnostic Test: Corvis ST; Diagnostic Test: Conrneal endothelial cell density
group (E)Control group (other eyes).
Receives: Diagnostic Test: Corvis ST; Diagnostic Test: Conrneal endothelial cell density

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Corneal Endothelial Cell Density (ECD)

    Measurement: Cells/mm², assessed via specular microscopy (Konan Noncon Robo NSP-9900).

    Measured: Baseline (preoperative), 1 month, 3 months, and 6 months postoperatively.

  2. Morphological Changes in Corneal Endothelium

    Parameters:

    Coefficient of Variation (CV): Reflects cell size variability (polymegathism).

    Hexagonality: Percentage of hexagonal cells (pleomorphism).

    Measurement: Specular microscopy.

    CV and hexagonality are vital for evaluating corneal endothelial health. Optimal outcomes are associated with low CV (<30%) and high hexagonality (>60%), while deviations signal pathology or risk. Specular microscopy remains the gold standard for non-invasive assessment.

    Measured: Baseline, 1, 3, and 6 months.

  3. Corneal Biomechanical Properties

    Parameters:

    Stress-Strain Index (SSI): Quantifies corneal stiffness.

    Deformation Amplitude (DA): Maximum corneal displacement during air-puff applanation.

    Measurement: Corvis ST (Oculus Optikgeräte GmbH).

    Normal Ranges:

    SSI: Typically ranges between ~50-100 (unitless), though values vary by population and device software.

    DA: Normal corneas average ~1.0-1.2 mm, while keratoconic corneas often exceed 1.3 mm.

    Measured: Baseline, 1, 3, and 6 months.

Secondary outcomes (3)
  1. Best-Corrected Visual Acuity (BCVA)

    Snellen charts converted to logMAR for analysis.

    Measured: Baseline, 1, 3, and 6 months.

  2. Intraocular Pressure (IOP)

    Goldmann applanation tonometry (average of three readings).

    Measured: Baseline, 1, 3, and 6 months.

  3. Correlation Between Corneal Changes and Clinical Outcomes

    Associations between ECD, biomechanical parameters (SSI/DA), and BCVA/IOP using regression models.

    Measured: Baseline, 1, 3, and 6 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2025
  2. Study start1 May 2022
  3. Primary completion1 Oct 2024
  4. Study completion31 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
80 participants (actual)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06861946
Sponsor's protocol ID
R241/R242
Status last verified
Mar 2025
First submitted
21 Feb 2025
Last updated
6 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Goezinne F, Nuijts RM, Liem AT, Lundqvist IJ, Berendschot TJ, Cals DW, Hendrikse F, La Heij EC. Corneal endothelial cell density after vitrectomy with silicone oil for complex retinal detachments. Retina. 2014 Feb;34(2):228-36. doi: 10.1097/IAE.0b013e3182979b88.

    PubMed 23807185
  • Latkowska M, Gajdzis M, Kaczmarek R. Emulsification of Silicone Oils: Altering Factors and Possible Complications-A Narrative Review. J Clin Med. 2024 Apr 20;13(8):2407. doi: 10.3390/jcm13082407.

    PubMed 38673681

Questions about this trial

What is this clinical trial studying?

An observational study of Silicon Oil Effect on Cornea and Corneal Biomechanics, run by Beni-Suef University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Corneal Endothelial Cell Density (ECD) (time frame: Baseline (preoperative), 1 month, 3 months, and 6 months postoperatively.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06861946, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in